Tarsus Pharmaceuticals, Inc.·4

Jun 17, 4:17 PM ET

LINK WILLIAM J PHD 4

Research Summary

AI-generated summary

Updated

Tarsus (TARS) Director William J. Link Sells 12,500 Shares

What Happened
William J. Link (Director) sold a total of 12,500 Tarsus (TARS) shares in open-market transactions on June 15, 2026 for aggregate proceeds of about $776,495. The sales break down as 10,572 shares at a weighted-average price of $61.97 (proceeds $655,147) and 1,928 shares at a weighted-average price of $62.94 (proceeds $121,348). These were dispositions (sales), not purchases.

Key Details

  • Transaction date: June 15, 2026; Form 4 filed June 17, 2026.
  • Sales: 10,572 shares at a weighted avg price $61.97 (range $61.67–$62.67 per footnote F2); 1,928 shares at weighted avg $62.94 (range $62.68–$63.05 per footnote F3).
  • Total shares sold: 12,500; total proceeds ≈ $776,495.
  • Shares owned after transaction: not disclosed in the information provided (see the Form 4 for post-transaction holdings).
  • Footnote F1: Sales were effected automatically under a Rule 10b5-1 trading plan adopted by Mr. Link on September 8, 2025. Footnotes F2 and F3 note weighted-average pricing and offer to provide per-price sale breakdowns on request.

Context
These sales were made under a prearranged 10b5-1 plan, which generally means the transactions were scheduled in advance and are commonly viewed as routine rather than a direct signal about the insider’s view of the company. For retail investors, purchases are typically more informative than routine sales; this filing simply reports that the director liquidated a portion of his holdings per the trading plan.